CA
NZ
UK
AU
IND
US
…
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Eterna Therapeutics Inc (ERNA) is a publicly listed biopharmaceutical company; publicly available information about its pipeline, assets and operations is limited. Long-term growth appears to depend on clinical development progress, regulatory milestones and commercial or licensing partnerships that could support revenue generation if successful.
Principal risks include early-stage development and execution risk, significant financing needs, the high probability of clinical or regulatory setbacks and limited public disclosure that hampers thorough evaluation.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -14.13M | -44.51M | -21.67M | -24.53M | -122.30M |
| Net income | -14.10M | -44.54M | -21.67M | -24.58M | -122.31M |
| Selling general administrative | 5.16M | 13.13M | 14.59M | 16.84M | 14.72M |
| Selling and marketing expenses | - | - | 0.00M | - | - |
| Gross profit | -0.26M | 0.49M | -0.17M | - | -5.76M |
| Reconciled depreciation | 0.26M | 1.64M | 0.73M | 0.50M | 0.46M |
| Ebit | -9.32M | -37.76M | -21.06M | -33.22M | 68.34M |
| Ebitda | -9.06M | -36.12M | -19.93M | -32.03M | 68.80M |
| Depreciation and amortization | 0.26M | 1.64M | 1.12M | 1.19M | 0.46M |
| Operating income | -9.32M | -15.67M | -21.14M | -33.22M | 68.34M |
| Other operating expenses | 9.32M | 16.26M | 21.20M | 27.23M | 27.43M |
| Interest expense | 0.03M | 6.75M | 0.61M | 0.03M | 0.07M |
| Tax provision | -0.04M | 0.03M | 0.04M | 0.04M | 0.01M |
| Interest income | 0.08M | 0.25M | 0.14M | - | - |
| Net interest income | 0.06M | -6.50M | -0.09M | -0.03M | -0.07M |
| Income tax expense | -0.04M | 0.03M | -0.00M | 0.04M | 0.01M |
| Total revenue | 0.00M | 0.58M | 0.07M | 0.00M | 0.00M |
| Total operating expenses | 9.06M | 16.16M | 20.97M | 27.23M | 27.43M |
| Cost of revenue | 0.26M | 0.10M | 0.24M | - | 5.76M |
| Total other income expense net | -4.81M | -28.84M | -0.54M | 8.68M | -190.64M |
| Net income from continuing ops | -14.08M | -44.54M | -20.00M | -24.58M | -122.31M |
| Net income applicable to common shares | - | - | - | -24.59M | -122.56M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5.83M | 5.27M | 49.13M | 22.28M | 32.43M |
| Intangible assets | - | - | - | - | 6.86M |
| Other current assets | 1.15M | 0.19M | 1.60M | 2.23M | 1.10M |
| Total liab | 3.43M | 3.57M | 46.90M | 10.17M | 25.93M |
| Total stockholder equity | 2.40M | 1.70M | 2.23M | 12.11M | 6.50M |
| Deferred long term liab | - | - | - | - | 5.99M |
| Other current liab | 1.77M | 1.01M | 3.10M | 3.99M | 0.25M |
| Common stock | 0.04M | 0.26M | 0.03M | 0.03M | 0.26M |
| Capital stock | 0.04M | 0.26M | 0.03M | 0.03M | 0.26M |
| Retained earnings | -245.64M | -231.54M | -186.98M | -165.30M | -159.70M |
| Other liab | - | - | - | 1.63M | 0.05M |
| Good will | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M |
| Other assets | - | - | - | 5.23M | 0.00M |
| Cash | 1.88M | 1.73M | 7.58M | 11.45M | 16.98M |
| Total current liabilities | 3.11M | 2.94M | 6.57M | 7.65M | 3.68M |
| Current deferred revenue | - | - | 0.19M | - | 1.25M |
| Net debt | -1.39M | -1.04M | 34.27M | -7.31M | -14.26M |
| Short term debt | 0.21M | 0.21M | 2.22M | 2.04M | 0.43M |
| Short long term debt | - | - | - | 1.75M | - |
| Short long term debt total | 0.49M | 0.68M | 41.84M | 4.14M | 2.72M |
| Other stockholder equity | 248.00M | 232.98M | 189.19M | 177.38M | 165.94M |
| Property plant equipment | - | - | - | 1.27M | 3.24M |
| Total current assets | 3.13M | 2.35M | 9.60M | 13.68M | 18.77M |
| Long term investments | - | - | 0.00M | 0.06M | 1.00M |
| Net tangible assets | - | - | - | 10.06M | 23.46M |
| Net receivables | 0.10M | 0.44M | 0.42M | 0.95M | 0.68M |
| Long term debt | - | - | 6.77M | 1.21M | - |
| Inventory | - | - | - | -0.95M | - |
| Accounts payable | 1.12M | 1.72M | 1.07M | 1.62M | 1.75M |
| Accumulated other comprehensive income | - | - | -0.00M | - | - |
| Non currrent assets other | 0.11M | 0.12M | 0.12M | 5.23M | 0.52M |
| Non current assets total | 2.70M | 2.92M | 39.53M | 8.60M | 13.66M |
| Capital lease obligations | 0.49M | 0.68M | 35.07M | 1.18M | 2.72M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.36M | 0.13M | -0.05M | -22.74M |
| Change to liabilities | - | - | - | 2.03M | -0.48M |
| Total cashflows from investing activities | -0.04M | -0.36M | -0.02M | -0.05M | -22.74M |
| Net borrowings | 2.25M | 5.29M | 16.50M | -0.00M | -0.94M |
| Total cash from financing activities | 7.21M | 6.26M | 16.56M | 19.58M | 61.59M |
| Change to operating activities | - | - | - | 1.68M | -1.15M |
| Net income | -14.08M | -44.54M | -21.67M | -24.58M | -122.31M |
| Change in cash | 0.15M | -9.94M | -3.87M | -1.44M | 15.36M |
| Begin period cash flow | 1.73M | 11.67M | 15.54M | 16.98M | 1.63M |
| End period cash flow | 1.88M | 1.73M | 11.67M | 15.54M | 16.98M |
| Total cash from operating activities | -7.02M | -15.84M | -20.41M | -20.98M | -23.49M |
| Issuance of capital stock | 4.93M | 1.14M | 8.03M | 19.71M | 62.52M |
| Depreciation | 0.26M | 1.64M | 1.12M | 0.50M | 0.46M |
| Other cashflows from investing activities | - | 0.00M | - | - | - |
| Dividends paid | - | 0.02M | 0.02M | -0.02M | -0.01M |
| Change to inventory | - | - | - | - | 0.48M |
| Change to account receivables | -0.41M | -0.01M | 0.53M | - | -0.66M |
| Sale purchase of stock | - | - | -16.25M | - | -22.85M |
| Other cashflows from financing activities | - | 0.97M | -0.25M | -0.11M | 0.01M |
| Change to netincome | - | - | - | -0.60M | 100.89M |
| Capital expenditures | 0.04M | 0.37M | 0.02M | 0.30M | 0.15M |
| Change in working capital | -0.05M | -1.98M | -2.12M | 3.71M | -2.35M |
| Stock based compensation | 1.50M | 1.52M | 1.24M | 2.94M | 5.24M |
| Other non cash items | 5.36M | 27.52M | 1.01M | -3.54M | 86.12M |
| Free cash flow | -7.05M | -16.20M | -20.43M | -21.27M | -23.64M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ERNA Eterna Therapeutics Inc |
0.02 0.99% |
2.04 | - | - | 1275.37 | 2.36 | 4581.99 | -0.29 |
| NVO Novo Nordisk A/S |
2.50 6.23% |
42.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.96 0.18% |
531.72 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-6.27 0.64% |
967.09 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Roger Sidhu M.D. | Chief Medical Officer | 1976 |
| Dr. Matthew Angel Ph.D. | CEO & Director | 1981 |
| Mr. Andrew C. Jackson | Chief Financial Officer | 1969 |
| Dr. Monil Shah M.B.A., Pharm.D. | Chief Operating Officer | NA |
| Ms. Sandra M. Gurrola | Principal Accounting Officer & VP of Fin. | 1967 |
| Ms. Lynn Sadowski Mason M.S. | Exec. VP of Clinical Operations | 1979 |
| Ms. Susan McClatchey | VP & Head of Quality | NA |
| Ms. Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior VP of Finance | 1967 |
| Mr. Sanjeev Luther | CEO, President & Director | 1962 |
| Ms. Dorothy J. Clarke | General Counsel & Director | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.55%
Communication Services
+1.42%
Consumer Cyclical
+1.74%
Consumer Defensive
+1.34%
Energy
-1.66%
Financial Services
+0.90%
Financials
-4.71%
Healthcare
+1.19%
Industrials
-0.04%
Real Estate
+0.78%
Technology
+1.00%
Utilities
+0.36%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...